Mazdutide (IBI362 / LY3305677) is a once-weekly peptide dual agonist of the GLP-1 receptor and glucagon receptor, derived from the oxyntomodulin scaffold and en…
Half-life
Approximately 7–10 days (supports once-weekly dosing)
Delivery
Once-weekly subcutaneous injection
Suggested dosage
Not specified
Usage
Studied for chronic weight management and metabolic health, including reductions in body weight, waist circumference, liver fat, and improvements in glycemic and cardiometabolic markers.
Mechanism of action
Co-activates GLP-1R to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite, while GCGR activation increases energy expenditure and promotes lipid mobilization; the combined signaling yields greater weight loss vs. GLP-1–only agonism in studies.
Benefits (4)
- Clinically meaningful body-weight reduction
- Appetite suppression and improved satiety
- Improved glycemic control and cardiometabolic markers
- Reductions in liver fat and waist circumference in trials
Side effects (5)
- Class-typical GI effects (nausea, vomiting, diarrhea/constipation)
- Decreased appetite
- Injection-site reactions
- Transient increases in pancreatic enzymes (e.g., lipase) reported
- Rare: gallbladder disease or pancreatitis (GLP-1 class consideration)
No purchase links available